دورية أكاديمية
Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil.
| العنوان: | Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil. |
|---|---|
| المؤلفون: | Wilhelm CM; Laboratório de Pesquisa em Resistência Bacteriana (LABRESIS), Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. Electronic address: camilawilhelm@gmail.com., Antochevis LC; Laboratório de Pesquisa em Resistência Bacteriana (LABRESIS), Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil., Magagnin CM; Laboratório de Pesquisa em Resistência Bacteriana (LABRESIS), Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil., Arns B; Infectious Diseases Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil., Vieceli T; Infectious Diseases Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil., Pereira DC; Serviço de Diagnóstico Laboratorial - Unidade de Microbiologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brasil., Lutz L; Serviço de Diagnóstico Laboratorial - Unidade de Microbiologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brasil., de Souza ÂC; Pontifícia Universidade Católica do Rio Grande do Sul, Hospital São Lucas - Setor de Microbiologia, Porto Alegre, Brasil., Dos Santos JN; Laboratório de Pesquisa em Resistência Bacteriana (LABRESIS), Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil., Guerra RR; Laboratório de Pesquisa em Resistência Bacteriana (LABRESIS), Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil., Medeiros GS; Intensive Care Service, Hospital Moinhos de Vento, Porto Alegre, Brazil., Santoro L; Department of Clinical Medicine, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil., Falci DR; Infectious Diseases Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Department of Clinical Medicine, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil., Rigatto MH; Infectious Diseases Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil., Barth AL; Laboratório de Pesquisa em Resistência Bacteriana (LABRESIS), Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil., Martins AF; Laboratório de Pesquisa em Resistência Bacteriana (LABRESIS), Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil., Zavascki AP; Infectious Diseases Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. |
| المصدر: | Journal of global antimicrobial resistance [J Glob Antimicrob Resist] 2024 Jun 25; Vol. 38, pp. 247-251. Date of Electronic Publication: 2024 Jun 25. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Published by Elsevier Ltd. on behalf of International Society of Chemotherapy for Infection and Cancer Country of Publication: Netherlands NLM ID: 101622459 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-7173 (Electronic) Linking ISSN: 22137165 NLM ISO Abbreviation: J Glob Antimicrob Resist Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Amsterdam : Published by Elsevier Ltd. on behalf of International Society of Chemotherapy for Infection and Cancer |
| مستخلص: | Introduction: Novel beta-lactam/beta-lactamase inhibitor (BIBLI) combinations are commercially available and have been used for treating carbapenem-resistant Klebsiella pneumoniae (CRKP) infections. Continuous surveillance of susceptibility profiles and resistance mechanism identification are necessary to monitor the evolution of resistance within these agents. Objective: The purpose of this study was to evaluate the susceptibility rates of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam in CRKP isolated from patients with bloodstream infections who underwent screening for a randomized clinical trial in Brazil. Methods: Minimum inhibitory concentrations (MICs) were determined for meropenem, ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam using the gradient diffusion strip method. Carbapenemase genes were detected by multiplex real-time polymerase chain reaction. Klebsiella pneumoniae carbapenemase (KPC)-producing isolates showing resistance to any BLBLI and New Delhi Metallo-beta-lactamase (NDM)-producing isolates with susceptibility to any BLBLI isolates were further submitted for whole-genome sequencing. Results: From a total of 69 CRKP isolates, 39 were positive for bla Competing Interests: Competing interests A.P.Z. is a research fellow of the National Council for Scientific and Technological Development (CNPq/Brazil). The authors have no relevant financial or non-financial interests to disclose. (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Beta-lactamase inhibitors; Carbapenemases; Ceftazidime/avibactam; Imipenem/relebactam; Klebsiella pneumoniae; Meropenem/vaborbactam |
| تواريخ الأحداث: | Date Created: 20240627 Latest Revision: 20240803 |
| رمز التحديث: | 20240804 |
| DOI: | 10.1016/j.jgar.2024.06.007 |
| PMID: | 38936472 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 2213-7173 |
|---|---|
| DOI: | 10.1016/j.jgar.2024.06.007 |